RecruitingPhase 4NCT07308717

Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

1,896 participants

Start Date

Dec 16, 2025

Study Type

INTERVENTIONAL

Conditions

Breast Cancer

Summary

This study aims to assess whether gabapentin should be a standard component of peri-operative pain control in mastectomy patients at Memorial Sloan Kettering Cancer Center.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria2

Age 18 to 65 years
Undergoing ambulatory extended recover (AXR) mastectomy (bilateral or unilateral) at the Josie Robertson Surgical Center (JSRC)

Exclusion Criteria1

None

Interventions

OTHERModification to Pre-operative Order Set

Modification to the pre-operative order set to remove gabapentin

Locations(7)

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (Limited protocol activities)

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, United States

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities)

Commack, New York, United States

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07308717

Related Trials

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT0661828763 locations

Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

NCT069260753 locations

EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients

NCT074780161 location

Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System

NCT052915071 location

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

NCT041190243 locations